The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Epstein, J. I., Amin, M. B., Reuter, V. R., & Mostofi, F. K. (1998) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199812000-00001 · Cited by 1,578
EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
Babjuk, M., Burger, M., Zigeuner, R., Shariat, S. F., van Rhijn, B. W. G., Compérat, E., Sylvester, R. J., Kaasinen, E., Böhle, A., Palou Redorta, J., et al. (2013) · European Urology · doi:10.1016/j.eururo.2013.06.003 · Cited by 1,174
EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2013 Guidelines
Witjes, J. A., Compérat, E., Cowan, N. C., De Santis, M., Gakis, G., Lebret, T., Ribal, M. J., Van der Heijden, A. G., & Sherif, A. (2014) · European Urology · doi:10.1016/j.eururo.2013.11.046 · Cited by 1,002
Self-citationLoehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106106 · Cited by 962
Gabrilove, J. L., Jakubowski, A., Scher, H., Sternberg, C., Wong, G., Grous, J., Yagoda, A., Fain, K., Moore, M. A. S., Clarkson, B., et al. (1988) · New England Journal of Medicine · doi:10.1056/nejm198806023182202 · Cited by 938
De Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Self-citationBellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Self-citationFrequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder
Gui, Y., Guo, G., Huang, Y., Hu, X., Tang, A., Gao, S., Wu, R., Chen, C., Li, X., Zhou, L., et al. (2011) · Nature Genetics · doi:10.1038/ng.907 · Cited by 747
Bajorin, D. F., Dodd, P. M., Mazumdar, M., Fazzari, M., McCaffrey, J. A., Scher, H. I., Herr, H., Higgins, G., & Boyle, M. G. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3173 · Cited by 728
Genome Sequencing Identifies a Basis for Everolimus Sensitivity
Iyer, G., Hanrahan, A. J., Milowsky, M. I., Al-Ahmadie, H., Scott, S. N., Janakiraman, M., Pirun, M., Sander, C., Socci, N. D., Ostrovnaya, I., et al. (2012) · Science · doi:10.1126/science.1226344 · Cited by 690
Fernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Piñeiro, L., Gonzalez, M., Portillo, J., Ojea, A., Pertusa, C., Rodriguez-Molina, J., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.016 · Cited by 660
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6979 · Cited by 526
Self-citationCoppin, C., Gospodarowicz, M. K., James, K. W., Tannock, I. F., Zee, B. C.-Y., Carson, J., Pater, J. L., & Sullivan, L. D. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.11.2901 · Cited by 472
Bellmunt, J., Choueiri, T. K., Fougeray, R., Schutz, F. A. B., Salhi, Y., Winquist, E., Culine, S., von der Maase, H., Vaughn, D. J., & Rosenberg, J. E. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4599 · Cited by 450
Self-citationGakis, G., Efstathiou, J., Lerner, S. P., Cookson, M. S., Keegan, K. A., Guru, K. A., Shipley, W. U., Heidenreich, A., Schoenberg, M. P., Sagaloswky, A. I., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.08.009 · Cited by 422
Vale, C. L. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.005 · Cited by 422
Leow, J. J., Martin-Doyle, W., Rajagopal, P. S., Patel, C. G., Anderson, E. M., Rothman, A. T., Cote, R. J., Urun, Y., Chang, S. L., Choueiri, T. K., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.033 · Cited by 411
Self-citationRadiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma
Hoskin, P. J., Rojas, A. M., Bentzen, S. M., & Saunders, M. I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.4950 · Cited by 332
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., Kim, P. H., Lin, O., Weinhold, N., Sander, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5740 · Cited by 309
Kamat, A. M., Hegarty, P. K., Gee, J. R., Clark, P. E., Svatek, R. S., Hegarty, N., Shariat, S. F., Xylinas, E., Schmitz-Dräger, B. J., Lotan, Y., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.09.057 · Cited by 263
Stimson, C. J., Chang, S. S., Barocas, D. A., Humphrey, J. E., Patel, S. G., Clark, P. E., Smith, J. A., & Cookson, M. S. (2010) · Journal of Urology · doi:10.1016/j.juro.2010.06.007 · Cited by 256
Frequent truncating mutations of STAG2 in bladder cancer
Solomon, D. A., Kim, J.-S., Bondaruk, J., Shariat, S. F., Wang, Z.-F., Elkahloun, A. G., Ozawa, T., Gerard, J., Zhuang, D., Zhang, S., et al. (2013) · Nature Genetics · doi:10.1038/ng.2800 · Cited by 208
Functional Copy-Number Alterations in Cancer
Taylor, B. S., Barretina, J., Socci, N. D., DeCarolis, P., Ladanyi, M., Meyerson, M., Singer, S., & Sander, C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003179 · Cited by 170 · cited 1×
“Moreover, aberrations of the chromatin remodelling genes (UTX,MLL-MLL3, CREBBP-EP300, NCOR1, ARID1A and CHD6) and, more recently, STAG2 mutations have also been documented in more than half of urothelial carcinomas, including lowand high-grade tumours [40, 42–44].”
BackgroundFernandez-Gomez, J., Madero, R., Solsona, E., Unda, M., Martinez-Piñeiro, L., Ojea, A., Portillo, J., Montesinos, M., Gonzalez, M., Pertusa, C., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.05.033 · Cited by 167
Ross, J. S., Wang, K., Al-Rohil, R. N., Nazeer, T., Sheehan, C. E., Otto, G. A., He, J., Palmer, G. A., Yelensky, R., Lipson, D., et al. (2013) · Modern Pathology · doi:10.1038/modpathol.2013.135 · Cited by 149
Al‐Ahmadie, H. A., Iyer, G., Janakiraman, M., Lin, O., Heguy, A., Tickoo, S. K., Fine, S. W., Gopalan, A., Chen, Y., Balar, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2892 · Cited by 88 · cited 1×
“In addition, a large proportion of urothelial tumours also harbour mutation and/or gene amplification that are potentially therapeutic targets, and these include FGFR3 mutations, PTEN deletions and FGFR1, CCND1 and MDM2 amplifications [41].”
BackgroundRadiotherapy for Bladder Cancer
Milosevic, M., Gospodarowicz, M. K., Zietman, A. L., Abbas, F., Haustermans, K. M., Moonen, L. M. F., Rödel, C. M., Schoenberg, M., & Shipley, W. U. (2007) · Urology · doi:10.1016/j.urology.2006.05.060 · Cited by 85
Cited by
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
Powles, T., Rosenberg, J. E., Sonpavde, G. P., Loriot, Y., Durán, I., Lee, J.-L., Matsubara, N., Vulsteke, C., Castellano, D., Wu, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035807 · Cited by 1,229
Fradet, Y., Bellmunt, J., Vaughn, D. J., Lee, J. L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., Necchi, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz127 · Cited by 480
Self-citationBellmunt, J., Hussain, M., Gschwend, J. E., Albers, P., Oudard, S., Castellano, D., Daneshmand, S., Nishiyama, H., Majchrowicz, M., Degaonkar, V., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00004-8 · Cited by 429
Self-citation
Metadata
- Authors
- Bellmunt, J., Orsola, A., Leow, J. J., Wiegel, T., De Santis, M., & Horwich, A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2014-09
- Volume
- 25
- Pages
- iii40-iii48
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W4313635027
- Cited by
- 335
- References
- 32
- FWCI
- 19.41
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.